Zetagen Therapeutics
Pharmaceuticals, 841 E Fayette St, Syracuse, New York, 13210, United States, 1-10 Employees
Phone Number: 13*********
Who is ZETAGEN THERAPEUTICS
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic in...
Read More
-
Headquarters: 841 E Fayette St, Syracuse, New York, 13210, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Joe Loy
Email
Phone
Industry: Pharmaceuticals
SIC Code: 5122
Does something look wrong? Fix it. | View contact records from ZETAGEN THERAPEUTICS
Zetagen Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Zetagen Therapeutics
Answer: Zetagen Therapeutics's headquarters are located at 841 E Fayette St, Syracuse, New York, 13210, United States
Answer: Zetagen Therapeutics's phone number is 13*********
Answer: Zetagen Therapeutics's official website is https://zetagen.com
Answer: Zetagen Therapeutics's revenue is $1 Million to $5 Million
Answer: Zetagen Therapeutics's SIC: 5122
Answer: Zetagen Therapeutics has 1-10 employees
Answer: Zetagen Therapeutics is in Pharmaceuticals
Answer: Zetagen Therapeutics contact info: Phone number: 13********* Website: https://zetagen.com
Answer: Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMetTM technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016. This novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. In addition to ZetaMetTM, the Companys pipeline includes other oncologic treatments for Skeletal Related Events (SREs), i.e., ZetaMet FlowableTM and ancillary osteologic treatments including, ZetaFuseTM, ZetaSetTM, ZetaDentTM and ZetaBaseTM. The Company is supported through Series A funding, private and angel investors, and Phase I and Phase II NIH research grants.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month